Did you know ? If you order before Friday 14h we deliver 90PCT of the the time next Tuesday, GENTAUR another in time delivery

Basic phospholipase A2 homolog bothropstoxin-1 (svPLA2 homolog) (BOJU-I) (Bothropstoxin I) (BthTx-I) (BtxtxI) (Myotoxic phospholipase A2-like) (Phospholipase A2 homolog 1)

 PA2B1_BOTJR             Reviewed;         137 AA.
Q90249; Q7LZ25; Q804D7;
05-DEC-2001, integrated into UniProtKB/Swiss-Prot.
22-JUL-2008, sequence version 3.
22-NOV-2017, entry version 101.
RecName: Full=Basic phospholipase A2 homolog bothropstoxin-1;
Short=svPLA2 homolog;
AltName: Full=BOJU-I;
AltName: Full=Bothropstoxin I;
Short=BthTx-I;
Short=BtxtxI;
AltName: Full=Myotoxic phospholipase A2-like;
AltName: Full=Phospholipase A2 homolog 1;
Flags: Precursor;
Bothrops jararacussu (Jararacussu).
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Lepidosauria; Squamata; Bifurcata; Unidentata; Episquamata;
Toxicofera; Serpentes; Colubroidea; Viperidae; Crotalinae; Bothrops.
NCBI_TaxID=8726;
[1]
NUCLEOTIDE SEQUENCE [MRNA].
TISSUE=Venom gland;
PubMed=15134836; DOI=10.1016/j.biochi.2004.02.002;
Kashima S., Roberto P.G., Soares A.M., Astolfi-Filho S., Pereira J.O.,
Giuliati S., Faria M. Jr., Xavier M.A.S., Fontes M.R.M., Giglio J.R.,
Franca S.C.;
"Analysis of Bothrops jararacussu venomous gland transcriptome
focusing on structural and functional aspects: I -- gene expression
profile of highly expressed phospholipases A2.";
Biochimie 86:211-219(2004).
[2]
NUCLEOTIDE SEQUENCE [MRNA].
TISSUE=Venom gland;
Hayashi M.A.F., Queiroz G.P., Radis-Baptista G., Yamane T.,
Camargo A.C.M.;
"Bothrops jararacussu myotoxic phospholipase A2-like mRNA.";
Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
[3]
PROTEIN SEQUENCE OF 17-137.
TISSUE=Venom;
PubMed=8427634; DOI=10.1007/BF01024915;
Cintra A.C.O., Marangoni S., Oliveira B., Giglio J.R.;
"Bothropstoxin-I: amino acid sequence and function.";
J. Protein Chem. 12:57-64(1993).
[4]
NUCLEOTIDE SEQUENCE [MRNA] OF 17-137.
TISSUE=Venom gland;
PubMed=7758974; DOI=10.1016/0378-1119(95)00099-R;
Ward R.J., Monesi N., Arni R.K., Larson R.E., Paco-Larson M.L.;
"Sequence of a cDNA encoding bothropstoxin I, a myotoxin from the
venom of Bothrops jararacussu.";
Gene 156:305-306(1995).
[5]
SEQUENCE REVISION.
Ward R.J.;
Submitted (SEP-2004) to the EMBL/GenBank/DDBJ databases.
[6]
PROTEIN SEQUENCE OF 17-137, AND DISULFIDE BONDS.
TISSUE=Venom;
PubMed=11732689; DOI=10.1023/A:1012228703756;
Cintra A.C.O., Sampaio S.V., Raghuvir A.K., Giglio J.R.;
"Assignment of the disulfide bridges in bothropstoxin-I, a myonecrotic
Lys49 PLA2 homolog from Bothrops jararacussu snake venom.";
J. Protein Chem. 20:377-382(2001).
[7]
PROTEIN SEQUENCE OF 17-26, FUNCTION, AND LETHAL DOSE.
PubMed=3176051; DOI=10.1016/0041-0101(88)90244-9;
Homsi-Brandeburgo M.I., Queiroz L.S., Santo-Neto H.,
Rodrigues-Simioni L., Giglio J.R.;
"Fractionation of Bothrops jararacussu snake venom: partial chemical
characterization and biological activity of bothropstoxin.";
Toxicon 26:615-627(1988).
[8]
FUNCTION, BIOASSAY, AND LETHAL DOSE.
TISSUE=Venom;
PubMed=11018293; DOI=10.1016/S0300-9084(00)01150-0;
Andriao-Escarso S.H., Soares A.M., Rodrigues V.M., Angulo Y., Diaz C.,
Lomonte B., Gutierrez J.M., Giglio J.R.;
"Myotoxic phospholipases A(2) in bothrops snake venoms: effect of
chemical modifications on the enzymatic and pharmacological properties
of bothropstoxins from Bothrops jararacussu.";
Biochimie 82:755-763(2000).
[9]
FUNCTION, BIOASSAY, LACK OF CATALYTIC ACTIVITY, AND MUTAGENESIS OF
HIS-63; LYS-64 AND LYS-128.
PubMed=11829743; DOI=10.1042/0264-6021:3620089;
Ward R.J., Chioato L., de Oliveira A.H., Ruller R., Sa J.M.;
"Active-site mutagenesis of a Lys49-phospholipase A2: biological and
membrane-disrupting activities in the absence of catalysis.";
Biochem. J. 362:89-96(2002).
[10]
FUNCTION, BIOASSAY, AND MUTAGENESIS OF LYS-121; LYS-122; TYR-123;
ARG-124; TYR-125; LYS-128; PHE-130; LYS-132 AND LYS-133.
PubMed=12079495; DOI=10.1042/BJ20020092;
Chioato L., De Oliveira A.H., Ruller R., Sa J.M., Ward R.J.;
"Distinct sites for myotoxic and membrane-damaging activities in the
C-terminal region of a Lys49-phospholipase A2.";
Biochem. J. 366:971-976(2002).
[11]
FUNCTION, BIOASSAY, AND MUTAGENESIS OF LYS-23; LYS-31; LYS-51; PRO-52;
LYS-53; ASP-54; ARG-58; TYR-61; HIS-63; LYS-68; LYS-69; 72-LYS-ARG-73;
LYS-87; GLU-93; LYS-99; LYS-106; THR-118; ASN-120; LYS-121; LYS-122;
TYR-123; ARG-124; TYR-125; HIS-126; LEU-127; LYS-128; PHE-130; LYS-132
AND LYS-133.
PubMed=17346668; DOI=10.1016/j.bbamem.2007.01.023;
Chioato L., Aragao E.A., Lopes Ferreira T., Medeiros A.I.,
Faccioli L.H., Ward R.J.;
"Mapping of the structural determinants of artificial and biological
membrane damaging activities of a Lys49 phospholipase A2 by scanning
alanine mutagenesis.";
Biochim. Biophys. Acta 1768:1247-1257(2007).
[12]
FUNCTION, AND MUTAGENESIS OF HIS-63; LYS-121; TYR-123; ARG-124;
LYS-128; PHE-130 AND LYS-133.
TISSUE=Venom;
PubMed=18160090; DOI=10.1016/j.toxicon.2007.11.004;
Aragao E.A., Chioato L., Ward R.J.;
"Permeabilization of E. coli K12 inner and outer membranes by
bothropstoxin-I, a Lys49 phospholipase A2 from Bothrops jararacussu.";
Toxicon 51:538-546(2008).
[13]
X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF 17-137, FUNCTION, SUBUNIT,
AND DISULFIDE BONDS.
TISSUE=Venom;
PubMed=17157889; DOI=10.1016/j.toxicon.2006.10.011;
Murakami M.T., Vicoti M.M., Abrego J.R.B., Lourenzoni M.R.,
Cintra A.C.O., Arruda E.Z., Tomaz M.A., Melo P.A., Arni R.K.;
"Interfacial surface charge and free accessibility to the PLA2-active
site-like region are essential requirements for the activity of Lys49
PLA2 homologues.";
Toxicon 49:378-387(2007).
[14]
X-RAY CRYSTALLOGRAPHY (1.83 ANGSTROMS) OF 17-137 IN COMPLEX WITH
ALPHA-TOCOPHEROL, SUBUNIT, AND DISULFIDE BONDS.
PubMed=19401234; DOI=10.1016/j.jsb.2009.04.003;
dos Santos J.I., Soares A.M., Fontes M.R.;
"Comparative structural studies on Lys49-phospholipases A(2) from
Bothrops genus reveal their myotoxic site.";
J. Struct. Biol. 167:106-116(2009).
[15]
X-RAY CRYSTALLOGRAPHY (1.48 ANGSTROMS) OF 17-137 ALONE; IN COMPLEX
WITH THE PLA2 INHIBITOR BROMOPHENACYL BROMIDE (BPB) AND IN COMPLEX
WITH POLYETHYLENE GLYCOL (PEG4), SUBUNIT, AND DISULFIDE BONDS.
TISSUE=Venom;
PubMed=20371382; DOI=10.1016/j.jsb.2010.03.019;
Fernandes C.A., Marchi-Salvador D.P., Salvador G.M., Silva M.C.,
Costa T.R., Soares A.M., Fontes M.R.;
"Comparison between apo and complexed structures of bothropstoxin-I
reveals the role of Lys122 and Ca(2+)-binding loop region for the
catalytically inactive Lys49-PLA(2)s.";
J. Struct. Biol. 171:31-43(2010).
-!- FUNCTION: Snake venom phospholipase A2 homolog that lacks
enzymatic activity. In vivo, induces muscle necrosis, accompanied
by polymorphonuclear cell infiltration, and edema in the mouse
paw. Damages artificial and myoblast membranes by a calcium-
independent mechanism. Has bactericidal activity.
{ECO:0000269|PubMed:11018293, ECO:0000269|PubMed:11829743,
ECO:0000269|PubMed:12079495, ECO:0000269|PubMed:17157889,
ECO:0000269|PubMed:17346668, ECO:0000269|PubMed:18160090,
ECO:0000269|PubMed:3176051}.
-!- SUBUNIT: Homodimer; non-covalently linked.
{ECO:0000269|PubMed:17157889, ECO:0000269|PubMed:19401234,
ECO:0000269|PubMed:20371382}.
-!- SUBCELLULAR LOCATION: Secreted.
-!- TISSUE SPECIFICITY: Expressed by the venom gland.
-!- TOXIC DOSE: LD(50) is 7.5-8.5 mg/kg by intraperitoneal injection
and 4.8 mg/kg by intravenous injection into mice.
{ECO:0000269|PubMed:11018293, ECO:0000269|PubMed:3176051}.
-!- SIMILARITY: Belongs to the phospholipase A2 family. Group II
subfamily. K49 sub-subfamily. {ECO:0000305}.
-!- CAUTION: Does not bind calcium as one of the calcium-binding sites
is lost (Asp->Lys in position 64, which corresponds to 'Lys-49' in
the current nomenclature). However, the hydrolytic activity is not
restored by the mutant containing an Asp-64, indicating that other
residues play a key role in hydrolytic activity. {ECO:0000305}.
-----------------------------------------------------------------------
Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
Distributed under the Creative Commons Attribution-NoDerivs License
-----------------------------------------------------------------------
EMBL; AY185200; AAO27453.1; -; mRNA.
EMBL; AY299391; AAP57527.1; -; mRNA.
EMBL; X78599; CAA55334.2; -; mRNA.
PIR; A30823; A30823.
PIR; PC4024; PC4024.
PDB; 2H8I; X-ray; 1.90 A; A/B=17-137.
PDB; 3CXI; X-ray; 1.83 A; A/B=17-137.
PDB; 3HZD; X-ray; 1.91 A; A/B=17-137.
PDB; 3HZW; X-ray; 2.28 A; A/B=17-127.
PDB; 3I03; X-ray; 1.48 A; A=17-137.
PDB; 3I3H; X-ray; 2.17 A; A/B=17-137.
PDB; 3I3I; X-ray; 1.82 A; A=17-137.
PDB; 3IQ3; X-ray; 1.55 A; A/B=17-137.
PDB; 4K06; X-ray; 2.08 A; A/B=17-137.
PDB; 4K09; X-ray; 2.11 A; A/B=17-135.
PDB; 4WTB; X-ray; 2.16 A; A/B=17-137.
PDBsum; 2H8I; -.
PDBsum; 3CXI; -.
PDBsum; 3HZD; -.
PDBsum; 3HZW; -.
PDBsum; 3I03; -.
PDBsum; 3I3H; -.
PDBsum; 3I3I; -.
PDBsum; 3IQ3; -.
PDBsum; 4K06; -.
PDBsum; 4K09; -.
PDBsum; 4WTB; -.
ProteinModelPortal; Q90249; -.
SMR; Q90249; -.
HOVERGEN; HBG008137; -.
EvolutionaryTrace; Q90249; -.
GO; GO:0005576; C:extracellular region; IEA:UniProtKB-SubCell.
GO; GO:0005509; F:calcium ion binding; IEA:InterPro.
GO; GO:0004623; F:phospholipase A2 activity; IEA:InterPro.
GO; GO:0090729; F:toxin activity; IEA:UniProtKB-KW.
GO; GO:0050482; P:arachidonic acid secretion; IEA:InterPro.
GO; GO:0042742; P:defense response to bacterium; IEA:UniProtKB-KW.
GO; GO:0016042; P:lipid catabolic process; IEA:InterPro.
GO; GO:0006644; P:phospholipid metabolic process; IEA:InterPro.
CDD; cd00125; PLA2c; 1.
Gene3D; 1.20.90.10; -; 1.
InterPro; IPR001211; PLipase_A2.
InterPro; IPR033112; PLipase_A2_Asp_AS.
InterPro; IPR016090; PLipase_A2_dom.
InterPro; IPR036444; PLipase_A2_dom_sf.
InterPro; IPR033113; PLipase_A2_His_AS.
PANTHER; PTHR11716; PTHR11716; 1.
Pfam; PF00068; Phospholip_A2_1; 1.
PRINTS; PR00389; PHPHLIPASEA2.
SMART; SM00085; PA2c; 1.
SUPFAM; SSF48619; SSF48619; 1.
PROSITE; PS00119; PA2_ASP; 1.
PROSITE; PS00118; PA2_HIS; 1.
1: Evidence at protein level;
3D-structure; Antibiotic; Antimicrobial; Direct protein sequencing;
Disulfide bond; Myotoxin; Secreted; Signal; Toxin.
SIGNAL 1 16 {ECO:0000269|PubMed:11732689,
ECO:0000269|PubMed:3176051,
ECO:0000269|PubMed:8427634}.
CHAIN 17 137 Basic phospholipase A2 homolog
bothropstoxin-1.
/FTId=PRO_0000161622.
DISULFID 42 131 {ECO:0000244|PDB:2H8I,
ECO:0000244|PDB:3CXI,
ECO:0000244|PDB:3HZD,
ECO:0000269|PubMed:17157889,
ECO:0000269|PubMed:19401234,
ECO:0000269|PubMed:20371382}.
DISULFID 44 60 {ECO:0000244|PDB:2H8I,
ECO:0000244|PDB:3CXI,
ECO:0000244|PDB:3HZD,
ECO:0000269|PubMed:17157889,
ECO:0000269|PubMed:19401234,
ECO:0000269|PubMed:20371382}.
DISULFID 59 111 {ECO:0000244|PDB:2H8I,
ECO:0000244|PDB:3CXI,
ECO:0000244|PDB:3HZD,
ECO:0000269|PubMed:17157889,
ECO:0000269|PubMed:19401234,
ECO:0000269|PubMed:20371382}.
DISULFID 65 137 {ECO:0000244|PDB:2H8I,
ECO:0000244|PDB:3CXI,
ECO:0000244|PDB:3HZD,
ECO:0000269|PubMed:17157889,
ECO:0000269|PubMed:19401234,
ECO:0000269|PubMed:20371382}.
DISULFID 66 104 {ECO:0000244|PDB:2H8I,
ECO:0000244|PDB:3CXI,
ECO:0000244|PDB:3HZD,
ECO:0000269|PubMed:17157889,
ECO:0000269|PubMed:19401234,
ECO:0000269|PubMed:20371382}.
DISULFID 73 97 {ECO:0000244|PDB:2H8I,
ECO:0000244|PDB:3CXI,
ECO:0000244|PDB:3HZD,
ECO:0000269|PubMed:17157889,
ECO:0000269|PubMed:19401234,
ECO:0000269|PubMed:20371382}.
DISULFID 91 102
VARIANT 19 19 F -> L.
VARIANT 37 37 Y -> H.
VARIANT 136 136 P -> A.
MUTAGEN 23 23 K->A: No change in myotoxicity when
injected into mice. No change in myoblast
membrane permeabilizing activities.
Important decrease in bactericidal
activity. No change in calcium-
independent damaging activity against
EYPC:DPPG liposomes. Decrease in calcium-
independent damaging activity against
EYPC:DMPA liposomes.
{ECO:0000269|PubMed:17346668}.
MUTAGEN 31 31 K->A: No change in myotoxicity when
injected into mice. No change in myoblast
membrane permeabilizing activities. No
change in bactericidal activity. No
change in calcium-independent damaging
activity against EYPC:DPPG liposomes.
Decrease in calcium-independent damaging
activity against EYPC:DMPA liposomes.
{ECO:0000269|PubMed:17346668}.
MUTAGEN 51 51 K->A: No change in myotoxicity when
injected into mice. No change in myoblast
membrane permeabilizing activities. No
change in bactericidal activity. Decrease
in calcium-independent damaging activity
against EYPC:DPPG liposomes. Decrease in
calcium-independent damaging activity
against EYPC:DMPA liposomes.
{ECO:0000269|PubMed:17346668}.
MUTAGEN 52 52 P->A: Important decrease in myotoxicity
when injected into mice. Decrease in
membrane permeabilization of cultured
myoblasts. No change in bactericidal
activity. No change in calcium-
independent damaging activity against
EYPC:DPPG liposomes. Increase in calcium-
independent damaging activity against
EYPC:DMPA liposomes.
{ECO:0000269|PubMed:17346668}.
MUTAGEN 53 53 K->A: No change in myotoxicity when
injected into mice. Decrease in myoblast
membrane permeabilizing activities. No
change in bactericidal activity.
Important decrease in calcium-independent
damaging activity against EYPC:DPPG
liposomes. Important decrease in calcium-
independent damaging activity against
EYPC:DMPA liposomes.
{ECO:0000269|PubMed:17346668}.
MUTAGEN 54 54 D->A: No change in myoblast membrane
permeabilizing activities.
{ECO:0000269|PubMed:17346668}.
MUTAGEN 58 58 R->A: No change in myotoxicity when
injected into mice. No change in myoblast
membrane permeabilizing activities. No
change in bactericidal activity. Decrease
in calcium-independent damaging activity
against EYPC:DPPG liposomes. Decrease in
calcium-independent damaging activity
against EYPC:DMPA liposomes.
{ECO:0000269|PubMed:17346668}.
MUTAGEN 61 61 Y->A: No change in myotoxicity when
injected into mice. No change in myoblast
membrane permeabilizing activities. No
change in bactericidal activity. Decrease
in calcium-independent damaging activity
against EYPC:DPPG liposomes. No change in
calcium-independent damaging activity
against EYPC:DMPA liposomes.
{ECO:0000269|PubMed:17346668}.
MUTAGEN 63 63 H->Q: No change in myotoxic activities.
No change in myoblast membrane
permeabilizing activities. No change in
bactericidal activity. No change in
calcium-independent membrane-damaging
activities. Shows no hydrolytic activity.
{ECO:0000269|PubMed:11829743,
ECO:0000269|PubMed:17346668,
ECO:0000269|PubMed:18160090}.
MUTAGEN 64 64 K->D: No change in myotoxic activities.
No change in calcium-independent
membrane-damaging and myotoxic
activities. Shows no hydrolytic activity.
{ECO:0000269|PubMed:11829743}.
MUTAGEN 68 68 K->A: No change in myotoxicity when
injected into mice. No change in myoblast
membrane permeabilizing activities. No
change in bactericidal activity. Decrease
in calcium-independent damaging activity
against EYPC:DPPG liposomes. Decrease in
calcium-independent damaging activity
against EYPC:DMPA liposomes.
{ECO:0000269|PubMed:17346668}.
MUTAGEN 69 69 K->A: Increase in myotoxicity when
injected into mice. Increase in myoblast
membrane permeabilizing activities. No
change in bactericidal activity. No
change in calcium-independent damaging
activity against EYPC:DPPG liposomes.
Decrease in calcium-independent damaging
activity against EYPC:DMPA liposomes.
{ECO:0000269|PubMed:17346668}.
MUTAGEN 71 71 T->KR: No change in myotoxicity when
injected into mice. No change in myoblast
membrane permeabilizing activities. No
change in bactericidal activity. No
change in calcium-independent damaging
activity against EYPC:DPPG liposomes. No
change in calcium-independent damaging
activity against EYPC:DMPA liposomes.
MUTAGEN 87 87 K->A: No change in myotoxicity when
injected into mice. No change in myoblast
membrane permeabilizing activities. No
change in bactericidal activity. No
change in calcium-independent damaging
activity against EYPC:DPPG liposomes.
Decrease in calcium-independent damaging
activity against EYPC:DMPA liposomes.
{ECO:0000269|PubMed:17346668}.
MUTAGEN 93 93 E->G: No change in myotoxicity when
injected into mice. Important decrease in
bactericidal activity. No change in
calcium-independent damaging activity
against EYPC:DPPG liposomes. No change in
calcium-independent damaging activity
against EYPC:DMPA liposomes.
{ECO:0000269|PubMed:17346668}.
MUTAGEN 99 99 K->A: No change in myotoxicity when
injected into mice. No change in myoblast
membrane permeabilizing activities. No
change in bactericidal activity. No
change in calcium-independent damaging
activity against EYPC:DPPG liposomes. No
change in calcium-independent damaging
activity against EYPC:DMPA liposomes.
{ECO:0000269|PubMed:17346668}.
MUTAGEN 106 106 K->A: Increase in myotoxicity when
injected into mice. No change in myoblast
membrane permeabilizing activities.
Decrease in bactericidal activity. No
change in calcium-independent damaging
activity against EYPC:DPPG liposomes.
Decrease in calcium-independent damaging
activity against EYPC:DMPA liposomes.
{ECO:0000269|PubMed:17346668}.
MUTAGEN 118 118 T->A: No change in myoblast membrane
permeabilizing activities. No change in
calcium-independent damaging activity
against EYPC:DPPG liposomes. No change in
calcium-independent damaging activity
against EYPC:DMPA liposomes.
{ECO:0000269|PubMed:17346668}.
MUTAGEN 120 120 N->A: No change in myotoxicity when
injected into mice. Increase in myoblast
membrane permeabilizing activities. No
change in bactericidal activity. No
change in calcium-independent damaging
activity against EYPC:DPPG liposomes. No
change in calcium-independent damaging
activity against EYPC:DMPA liposomes.
{ECO:0000269|PubMed:17346668}.
MUTAGEN 121 121 K->A: No change in myotoxicity when
injected into mice. Decrease in myoblast
membrane permeabilizing activities.
Important decrease in bactericidal
activity. Important decrease in calcium-
independent damaging activity against
EYPC:DPPG liposomes. Important decrease
in calcium-independent damaging activity
against EYPC:DMPA liposomes.
{ECO:0000269|PubMed:12079495,
ECO:0000269|PubMed:17346668,
ECO:0000269|PubMed:18160090}.
MUTAGEN 122 122 K->A: No change in myotoxicity when
injected into mice. Decrease in myoblast
membrane permeabilizing activities.
Decrease in bactericidal activity.
Important decrease in calcium-independent
damaging activity against EYPC:DPPG
liposomes. Decrease in calcium-
independent damaging activity against
EYPC:DMPA liposomes.
{ECO:0000269|PubMed:12079495,
ECO:0000269|PubMed:17346668}.
MUTAGEN 123 123 Y->A: Important decrease in myotoxicity
when injected into mice. Important
decrease in myoblast membrane
permeabilizing activities. Important
decrease in bactericidal activity.
Decrease in calcium-independent damaging
activity against EYPC:DPPG liposomes.
Decrease in calcium-independent damaging
activity against EYPC:DMPA liposomes.
{ECO:0000269|PubMed:12079495,
ECO:0000269|PubMed:17346668,
ECO:0000269|PubMed:18160090}.
MUTAGEN 123 123 Y->W: No change (PubMed:17346668) or
important decrease (PubMed:12079495) in
myotoxicity when injected into mice. No
change in myoblast membrane
permeabilizing activities. Decrease in
bactericidal activity. No change in
calcium-independent damaging activity
against EYPC:DPPG liposomes. Important
increase in calcium-independent damaging
activity against EYPC:DMPA liposomes.
{ECO:0000269|PubMed:12079495,
ECO:0000269|PubMed:17346668,
ECO:0000269|PubMed:18160090}.
MUTAGEN 124 124 R->A: Important decrease in myotoxicity
when injected into mice. Decrease in
myoblast membrane permeabilizing
activities. Important decrease in
bactericidal activity. Important decrease
in calcium-independent damaging activity
against EYPC:DPPG liposomes. No change in
calcium-independent damaging activity
against EYPC:DMPA liposomes.
{ECO:0000269|PubMed:12079495,
ECO:0000269|PubMed:17346668,
ECO:0000269|PubMed:18160090}.
MUTAGEN 125 125 Y->A: Important decrease in myotoxicity
when injected into mice. Decrease in
myoblast membrane permeabilizing
activities. Decrease in bactericidal
activity. Important decrease in calcium-
independent damaging activity against
EYPC:DPPG liposomes. Important decrease
in calcium-independent damaging activity
against EYPC:DMPA liposomes.
{ECO:0000269|PubMed:12079495,
ECO:0000269|PubMed:17346668}.
MUTAGEN 125 125 Y->W: No change in myotoxicity when
injected into mice. No change in myoblast
membrane permeabilizing activities.
Decrease in bactericidal activity. No
change in calcium-independent damaging
activity against EYPC:DPPG liposomes. No
change in calcium-independent damaging
activity against EYPC:DMPA liposomes.
{ECO:0000269|PubMed:12079495,
ECO:0000269|PubMed:17346668}.
MUTAGEN 126 126 H->A: No change in myotoxicity when
injected into mice. No change in myoblast
membrane permeabilizing activities.
Important decrease in bactericidal
activity. Decrease in calcium-independent
damaging activity against EYPC:DPPG
liposomes. Decrease in calcium-
independent damaging activity against
EYPC:DMPA liposomes.
{ECO:0000269|PubMed:17346668}.
MUTAGEN 127 127 L->A: No change in myotoxicity when
injected into mice. No change in myoblast
membrane permeabilizing activities.
Decrease in bactericidal activity.
Important decrease in calcium-independent
damaging activity against EYPC:DPPG
liposomes. Important decrease in calcium-
independent damaging activity against
EYPC:DMPA liposomes.
{ECO:0000269|PubMed:17346668}.
MUTAGEN 128 128 K->A: Important decrease in myotoxicity
when injected into mice. Important
decrease in myoblast membrane
permeabilizing activities. Important
decrease in bactericidal activity.
Important decrease in calcium-independent
damaging activity against EYPC:DPPG
liposomes. Important decrease in calcium-
independent damaging activity against
EYPC:DMPA liposomes. Shows no hydrolytic
activity. {ECO:0000269|PubMed:11829743,
ECO:0000269|PubMed:12079495,
ECO:0000269|PubMed:17346668,
ECO:0000269|PubMed:18160090}.
MUTAGEN 130 130 F->A: Important decrease in myotoxicity
when injected into mice. Decrease in
myoblast membrane permeabilizing
activities. Decrease in bactericidal
activity. Important decrease in calcium-
independent damaging activity against
EYPC:DPPG liposomes. Important decrease
in calcium-independent damaging activity
against EYPC:DMPA liposomes.
{ECO:0000269|PubMed:12079495,
ECO:0000269|PubMed:17346668,
ECO:0000269|PubMed:18160090}.
MUTAGEN 130 130 F->W: No change in myotoxicity when
injected into mice. No change in myoblast
membrane permeabilizing activities.
Decrease in bactericidal activity. No
change in calcium-independent damaging
activity against EYPC:DPPG liposomes.
Decrease (PubMed:17346668) or important
decrease (PubMed:12079495) in calcium-
independent damaging activity against
EYPC:DMPA liposomes.
{ECO:0000269|PubMed:12079495,
ECO:0000269|PubMed:17346668,
ECO:0000269|PubMed:18160090}.
MUTAGEN 132 132 K->A: No change in myotoxicity when
injected into mice. Important decrease in
calcium-independent damaging activity
against EYPC:DPPG liposomes. No change in
calcium-independent damaging activity
against EYPC:DMPA liposomes.
{ECO:0000269|PubMed:12079495,
ECO:0000269|PubMed:17346668}.
MUTAGEN 133 133 K->A: No change in myotoxicity when
injected into mice. No change in myoblast
membrane permeabilizing activities.
Decrease in bactericidal activity. No
change in calcium-independent damaging
activity against EYPC:DPPG liposomes. No
change in calcium-independent damaging
activity against EYPC:DMPA liposomes.
{ECO:0000269|PubMed:12079495,
ECO:0000269|PubMed:17346668,
ECO:0000269|PubMed:18160090}.
CONFLICT 23 23 K -> H (in Ref. 7; AA sequence).
{ECO:0000305}.
CONFLICT 74 74 D -> N (in Ref. 3; AA sequence).
{ECO:0000305}.
HELIX 18 29 {ECO:0000244|PDB:3I03}.
HELIX 33 37 {ECO:0000244|PDB:3I03}.
STRAND 38 40 {ECO:0000244|PDB:3CXI}.
TURN 41 43 {ECO:0000244|PDB:3I03}.
STRAND 44 47 {ECO:0000244|PDB:3I03}.
HELIX 55 67 {ECO:0000244|PDB:3I03}.
TURN 75 77 {ECO:0000244|PDB:3I03}.
STRAND 82 85 {ECO:0000244|PDB:3I03}.
STRAND 88 91 {ECO:0000244|PDB:3I03}.
HELIX 96 114 {ECO:0000244|PDB:3I03}.
HELIX 116 118 {ECO:0000244|PDB:3I03}.
HELIX 121 123 {ECO:0000244|PDB:3I03}.
HELIX 128 130 {ECO:0000244|PDB:3I03}.
SEQUENCE 137 AA; 15497 MW; 7BE006BABC4DFC39 CRC64;
MRTLWIMAVL LVGVEGSLFE LGKMILQETG KNPAKSYGAY GCNCGVLGRG KPKDATDRCC
YVHKCCYKKL TGCDPKKDRY SYSWKDKTIV CGENNPCLKE LCECDKAVAI CLRENLGTYN
KKYRYHLKPF CKKADPC


Related products :

Catalog number Product name Quantity
EIAAB31490 Choline phosphatase 3,HindIII K4L homolog,Homo sapiens,Hu-K4,Human,Phosphatidylcholine-hydrolyzing phospholipase D3,Phospholipase D3,PLD 3,PLD3
EIAAB31409 Bos taurus,Bovine,LAMA-like protein 1,Lamina ancestor homolog 1,Phospholipase B domain-containing protein 1,Phospholipase B-like 1,PLBD1
EIAAB31411 LAMA-like protein 1,Lamina ancestor homolog 1,Phospholipase B domain-containing protein 1,Phospholipase B-like 1,Plbd1,Rat,Rattus norvegicus
EIAAB31410 LAMA-like protein 1,Lamina ancestor homolog 1,Mouse,Mus musculus,Phospholipase B domain-containing protein 1,Phospholipase B-like 1,Plbd1
EIAAB31408 Homo sapiens,Human,LAMA-like protein 1,Lamina ancestor homolog 1,Phospholipase B domain-containing protein 1,Phospholipase B-like 1,PLBD1
EIAAB31414 Bos taurus,Bovine,LAMA-like protein 2,Lamina ancestor homolog 2,Phospholipase B domain-containing protein 2,PLBD2,Putative phospholipase B-like 2
EIAAB10717 DDHD domain-containing protein 1,Ddhd1,Mouse,Mus musculus,PA-PLA1,Phosphatidic acid-preferring phospholipase A1 homolog,Phospholipase DDHD1
EIAAB31413 LAMA-like protein 2,Lamina ancestor homolog 2,Phospholipase B domain-containing protein 2,Plbd2,Putative phospholipase B-like 2,Rat,Rattus norvegicus,RDCR-0918-3
EIAAB10716 DDHD domain-containing protein 1,DDHD1,Homo sapiens,Human,KIAA1705,PA-PLA1,Phosphatidic acid-preferring phospholipase A1 homolog,Phospholipase DDHD1
EIAAB31407 Oryctolagus cuniculus,Phospholipase AdRab-B,Phospholipase B,Phospholipase B_lipase,Phospholipase B1, membrane-associated,PLB_LIP,PLB1,Rabbit
EIAAB31412 76 kDa protein,Homo sapiens,Human,LAMA-like protein 2,Lamina ancestor homolog 2,p76,Phospholipase B domain-containing protein 2,PLBD2,Putative phospholipase B-like 2
EIAAB31415 66.3 kDa protein,76 kDa protein,LAMA-like protein 2,Lamina ancestor homolog 2,Mouse,Mus musculus,p76,Phospholipase B domain-containing protein 2,Plbd2,Putative phospholipase B-like 2
EIAAB31461 1-phosphatidylinositol-4,5-bisphosphate phosphodiesterase eta-2,Mouse,Mus musculus,Phosphoinositide phospholipase C-eta-2,Phosphoinositide phospholipase C-like 4,Phospholipase C-eta-2,Phospholipase C-
EIAAB29736 Adipose-specific phospholipase A2,AdPLA,Group XVI phospholipase A2,Homo sapiens,HRAS-like suppressor 1,HRAS-like suppressor 3,HRASLS3,H-rev 107 protein homolog,HREV107,HREV107-1,HREV107-3,HRSL3,Human,
EIAAB31405 Homo sapiens,hPLB,Human,Phospholipase B,Phospholipase B_lipase,Phospholipase B1, membrane-associated,PLB,PLB_LIP,PLB1
EIAAB31404 Phlpb,Phospholipase B,Phospholipase B_lipase,Phospholipase B1, membrane-associated,PLB_LIP,Plb1,Rat,Rattus norvegicus
EIAAB31460 1-phosphatidylinositol-4,5-bisphosphate phosphodiesterase eta-1,Kiaa1069,Mouse,Mus musculus,Phosphoinositide phospholipase C-eta-1,Phospholipase C-eta-1,Phospholipase C-like protein 3,PLC-eta-1,Plch1,
EIAAB31406 Mouse,Mus musculus,Phospholipase B,Phospholipase B_lipase,Phospholipase B1, membrane-associated,Plb,PLB_LIP,Plb1
EIAAB31459 1-phosphatidylinositol-4,5-bisphosphate phosphodiesterase eta-1,Homo sapiens,Human,KIAA1069,Phosphoinositide phospholipase C-eta-1,Phospholipase C-eta-1,Phospholipase C-like protein 3,PLC-eta-1,PLCH1,
EIAAB29640 GIIC sPLA2,Group IIA phospholipase A2,Homo sapiens,Human,Non-pancreatic secretory phospholipase A2,NPS-PLA2,Phosphatidylcholine 2-acylhydrolase 2A,Phospholipase A2, membrane associated,PLA2B,PLA2G2A,P
EIAAB30907 Glycoprotein phospholipase D,Glycosyl-phosphatidylinositol-specific phospholipase D,GPI-PLD,GPI-specific phospholipase D,GPLD1,Homo sapiens,Human,Phosphatidylinositol-glycan-specific phospholipase D,P
EIAAB30908 Bos taurus,Bovine,Glycoprotein phospholipase D,Glycosyl-phosphatidylinositol-specific phospholipase D,GPI-PLD,GPI-specific phospholipase D,GPLD1,Phosphatidylinositol-glycan-specific phospholipase D,PI
EIAAB30909 Glycoprotein phospholipase D,Glycosyl-phosphatidylinositol-specific phospholipase D,GPI-PLD,GPI-specific phospholipase D,Gpld1,Mouse,Mus musculus,Phosphatidylinositol-glycan-specific phospholipase D,P
10-663-45314 Secreted Phospholipase A2-IIA (sPLA2-IIA) Human - EC 3.1.1.4; Phosphatidylcholine 2-acylhydrolase; Group IIA phospholipase A2; GIIC sPLA2; Non-pancreatic secretory phospholipase A2; NPS-PLA2 N_A 1 mg
10-663-45314 Secreted Phospholipase A2-IIA (sPLA2-IIA) Human - EC 3.1.1.4; Phosphatidylcholine 2-acylhydrolase; Group IIA phospholipase A2; GIIC sPLA2; Non-pancreatic secretory phospholipase A2; NPS-PLA2 N_A 0.002 mg


 

GENTAUR Belgium BVBA BE0473327336
Voortstraat 49, 1910 Kampenhout BELGIUM
Tel 0032 16 58 90 45

Fax 0032 16 50 90 45
info@gentaur.com | Gentaur





GENTAUR Ltd.
Howard Frank Turnberry House
1404-1410 High Road
Whetstone London N20 9BH
Tel 020 3393 8531 Fax 020 8445 9411
uk@gentaur.com | Gentaur

 

 




GENTAUR France SARL
9, rue Lagrange, 75005 Paris
Tel 01 43 25 01 50

Fax 01 43 25 01 60
RCS Paris B 484 237 888

SIRET 48423788800017

BNP PARIBAS PARIS PL MAUBERT BIC BNPAFRPPPRG

france@gentaur.com | Gentaur

GENTAUR GmbH
Marienbongard 20
52062 Aachen Deutschland
Support Karolina Elandt
Tel: 0035929830070
Fax: (+49) 241 56 00 47 88

Logistic :0241 40 08 90 86
Bankleitzahl 39050000
IBAN lautet DE8839050000107569353
Handelsregister Aachen HR B 16058
Umsatzsteuer-Identifikationsnummer *** DE 815175831
Steuernummer 201/5961/3925
de@gentaur.com | Gentaur

GENTAUR U.S.A
Genprice Inc, Logistics
547, Yurok Circle
San Jose, CA 95123
CA 95123
Tel (408) 780-0908,
Fax (408) 780-0908,
sales@genprice.com

Genprice Inc, Invoices and accounting
6017 Snell Ave, Ste 357
San Jose, CA 95123




GENTAUR Nederland BV
NL850396268B01 KVK nummer 52327027
Kuiper 1
5521 DG Eersel Nederland
Tel:  0208-080893  Fax: 0497-517897
nl@gentaur.com | Gentaur
IBAN: NL04 RABO 0156 9854 62   SWIFT RABONL2U






GENTAUR Spain
tel:0911876558
spain@gentaur.com | Gentaur






ГЕНТАУЪР БЪЛГАРИЯ
ID # 201 358 931 /BULSTAT
София 1000, ул. "Граф Игнатиев" 53 вх. В, ет. 2
Tel 0035924682280 Fax 0035924808322
e-mail: Sofia@gentaur.com | Gentaur
IBAN: BG11FINV91501014771636
BIC: FINVBGSF

GENTAUR Poland Sp. z o.o.


ul. Grunwaldzka 88/A m.2
81-771 Sopot, Poland
TEL Gdansk 058 710 33 44 FAX  058 710 33 48              

poland@gentaur.com | Gentaur

Other countries

Österreich +43720880899

Canada Montreal +15149077481

Ceská republika Praha +420246019719

Danmark +4569918806

Finland Helsset +358942419041

Magyarország Budapest +3619980547

Ireland Dublin+35316526556

Luxembourg+35220880274

Norge Oslo+4721031366

Sverige Stockholm+46852503438

Schweiz Züri+41435006251

US New York+17185132983

GENTAUR Italy
SRL IVA IT03841300167
Piazza Giacomo Matteotti, 6
24122 Bergamo Tel 02 36 00 65 93
Fax 02 36 00 65 94
italia@gentaur.com | Gentaur